• Redwood Pharma begins production of active ingredient in RP101 for Phase II studies

    Medicines that are used in clinical trials are stringently regulated. Regulated production begins now of the active pharmaceutical ingredient in RP101, which will be used in the clinical Phase II trial scheduled for the coming fall. RP101 is a new medical treatment for post-menopausal women suffering from chronic dry eye disease. Medicines used in clinical […]

  • Redwood Pharma initiates toxicological safety studies

    Redwood Pharma AB (publ) now begins toxicological safety studies for its drug development project RP101. The results will initially be incorporated into the Company’s application for permission to perform the clinical Phase II trial, which represents the next stage of development for RP101. Development work continues according to plan. The Company’s drug development project RP101, […]

  • New US patent approved

    Redwood Pharma’s licensor, Broda Technologies, has been granted an additional patent in the US regarding the IntelliGel drug delivery platform. The new patent is maximally valid until 21 March 2031 and represents additional protection of IntelliGel, which in turn becomes even more commercially attractive in the US market for prescription-based pharmaceuticals applied to the eye. […]

  • Redwood Pharma AB (publ) End of Year Report 2016

    Redwood Pharma AB (publ), End of Year Report 2016 January – December 2016. The period January 1 – December 31, 2016 • Net Revenues KSEK 0 (0) • Operating Loss KSEK -8 736 (-166) • Loss per Share SEK -1,75 (-14,90) 2016 Fourth Quarter (October 1 – December 31) • Net Revenues KSEK 0 (0) […]

  • Eye expert to support Redwood Pharma

    In preparation for the upcoming pharmaceutical clinical trial of RP101, Redwood Pharma AB (publ) has retained Associate Professor Gerhard Garhöfer of the Medical University of Vienna as a medical advisor. Professor Garhöfer is a leading expert in ophthalmology in Europe and has extensive experience in treating patients with Dry Eye Disease. Professor Garhöfer is currently […]

  • Redwood Pharma has developed a process for manufacture of the drug RP101 for coming safety studies

    January 16, 2017, Stockholm: Redwood Pharma AB (publ) has now according to plan completed optimization work surrounding the manufacturing process of RP101 that is needed for the coming safety studies. RP101 represents the combination of the company’s active substance and the IntelliGel® drug delivery platform. Production of RP101 for the safety studies will now begin. […]

  • Development of Redwood Pharma’s RP101 ophthalmic therapy continues according to plan along with value-enhancing networking

    The pace of Redwood Pharma development activities surrounding the company’s dry eye ophthalmic therapy RP101 has been high during the fall of 2016. Our spring IPO on AktieTorget where the company raised SEK 15 million has intensified development of RP101 while the firm has not experienced any setbacks. This has enabled the company to participate […]

  • Redwood Pharma AB appoints Ulf Björklund as Chief Medical Officer

    Redwood Pharma AB (publ), a company that develops pharmaceuticals within ophthalmology, announces today that Ulf Björklund has accepted the company’s offer to become Chief Medical Officer (CMO). In this role, Ulf Björklund will oversee clinical development of the Company’s new product candidate RP101 a therapy to treat chronic Dry Eye Disease in post-menopausal women. The […]